Current issue

April 2016

Volume 54

Issue 4

Welcome to Drug and Therapeutics Bulletin (DTB)

For 50 years, Drug and Therapeutics Bulletin (DTB) has provided rigorous and independent evaluations of, and practical advice on, individual treatments and the overall management of disease for doctors, pharmacists and other healthcare professionals.

DTB has always been wholly independent of the pharmaceutical industry, Government and regulatory authorities. DTB is also free of advertising and other forms of commercial sponsorship.

Andrew Herxheimer (1925-2016)

It is with great sadness that we report that Andrew Herxheimer, founding editor of DTB, has died. Andrew set up the Bulletin in 1962 to provide rigorous, independent and unbiased evaluations of drugs and other therapeutic interventions. He continued to edit it for over 30 years and, under his leadership, DTB became a well-respected and influential publication committed to the provision of clear, concise and practical information on the use of medicines. We offer our condolences to Andrew’s family.

Read the full obituary >>

Read Andrew's first issue published in 1962 and final issue in 1992 >>

DTB podcasts

Listen to the latest DTB podcast, with Editor in Chief James Cave and Deputy Editor David Phizackerley discussing this month's issue:

Listen to the latest podcast >>
Previous podcasts >>

Free sample issue

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of DTB: now:

View free sample issue >>

Sign up for eTOC alerts >>

Upcoming topics

Upcoming DTB topics include:

Oxycodone/naloxone for restless legs syndrome

Religious and cultural beliefs and medicines

Midodrine for orthostatic hypotension

Guanfacine for ADHD

Sacubitril/valsartan for heart failure

Polypharmacy and Empagliflozin reviewed

DTB education

Read educational articles published in DTB and then test your knowledge on BMJ Learning:

Test your knowledge >>

Follow DTB

Keep up to date with the latest news and content from the journal.

Twitter >>

Facebook>>

Email Alerts >>